Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions
Brief Summary: Objectives

1. To evaluate the safety and long-term effectiveness of coronary stenting with the Everolimus-eluting coronary stent system(EECSS) (XIENCETM V, Abbott Vascular, Santa Clara, CA, PromusTM, Boston Scientific, Natick, MA), compared with the sirolimus-eluting coronary stent system(SECSS) (CypherTM, Cordis Johnson \& Johnson, Warren, NJ) in the treatment of coronary stenosis.
2. To evaluate the safety and efficacy of 6-month clopidogrel therapy compared with 12-month clopidogrel therapy.

Study Design: Prospective, open label, two-arm, randomized multi-center trial to test the non-inferiority of EECSS compared with the SECSS, and to test the non-inferiority of 6 months duration compared with 12 months duration of clopidogrel therapy. Patients will be randomized in a two by two factorial manner according to the type of drug eluting stent (EECSS vs. SECSS) and the duration of dual anti-platelet therapy (6 months vs. 12 months). Randomization will also be stratified per hospital for the presence of DM and the presence of long lesions (lesion length ≥ 28mm)

Patient Enrollment: 1,372 patients enrolled at 17 centers in Korea.

Patient Follow-Up: Clinical follow-up will occur at 1, 3, and 9 months, and at 1, 2, 3, 4, and 5 years. Investigator or designee may conduct follow-up as telephone contacts or office visits.

Primary Endpoint

* In-segment late luminal loss (LL) at 9 months for comparison of stenting with EECSS vs. SECSS.
* Target vessel failure (TVF) (cardiac death, myocardial infarction, ischemia driven target vessel revascularization) at 12 months for comparison of 6 months vs. 12 months of clopidogrel therapy

Secondary Endpoint

* All Death
* Cardiac death
* Myocardial infarction
* Target vessel revascularization (TVR) (all and ischemia-driven)
* Target lesion revascularization (TLR) (all and ischemia-driven)
* Stent thrombosis
* Acute success (device, lesion, and procedure)
* Bleeding
* Cerebrovascular accident
* In-stent LL at 9 months
* Angiographic pattern of restenosis at 9-month angiographic follow-up
* In-stent and in-segment % diameter stenosis (%DS) at 9 months
* In-stent % volume obstruction (%VO) at 9 months
* Incomplete stent apposition post index procedure
* Persisting incomplete stent apposition, late-acquired incomplete stent apposition, aneurysm, thrombosis, and persisting dissection at 9 months


Options:
A: Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): N/A
B: Arm Label: E6; Type: EXPERIMENTAL; Interventions: Device: Everolimus-eluting stent (Xience or Promus), Drug: 6-month clopidogrel therapy | Arm Label: S6; Type: ACTIVE_COMPARATOR; Interventions: Device: Sirolimus-eluting stent (Cypher), Drug: 6-month clopidogrel therapy | Arm Label: E12; Type: EXPERIMENTAL; Interventions: Device: Everolimus-eluting stent (Xience or Promus), Drug: 12-month clopidogrel therapy | Arm Label: S12; Type: ACTIVE_COMPARATOR; Interventions: Device: Sirolimus-eluting stent (Cypher), Drug: 12-month clopidogrel therapy | Intervention Type: DEVICE; Name: Everolimus-eluting stent (Xience or Promus); Assigned to Arm(s): E12, E6 | Intervention Type: DEVICE; Name: Sirolimus-eluting stent (Cypher); Assigned to Arm(s): S12, S6 | Intervention Type: DRUG; Name: 6-month clopidogrel therapy; Assigned to Arm(s): E6, S6 | Intervention Type: DRUG; Name: 12-month clopidogrel therapy; Assigned to Arm(s): E12, S12
C: Arm Label: Aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: Aspirin,Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin,Clopidogrel | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Aspirin,Clopidogrel; Assigned to Arm(s): Aspirin,Clopidogrel
D: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin monotherapy | Arm Label: Aspirin,Clopidogrel; Type: EXPERIMENTAL; Interventions: Drug: Aspirin,Clopidogrel | Intervention Type: DRUG; Name: Aspirin monotherapy; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Aspirin,Clopidogrel; Assigned to Arm(s): Aspirin,Clopidogrel

Answer: B